Tubulis GmbH’s Post

As of last week's ISCT conference, the cat is finally out of the bag on Ori's novel technology and superior biological performance. As someone who has been in the middle of this maturing industry for over 15 years, I am convinced that this is the step change in manufacturing that the industry so urgently needs. Check it out via our website and form your own opinion ..... and get yourself lined up for a demo!

Interested in learning more about Ori Biotech's new #IRO manufacturing platform? More detail and data showcasing our ability to automate better biology in the release below. #CGT #CellTherapy #Biotechnology

Hope to see you in Glasgow! For RayStation we have a lot of exciting news on display at the conference: 💎 A new module for fast automated replanning, that can enable daily and online adaptations. 💎 Automatic image import directly followed by deep-learning segmentation (DLS). 💎 Improved speed of DLS and a large range of new models, including guideline-based H&N lymph nodes and brachial plexus. 💎 SRS planning tools for conventional linacs to treat multiple targets. This tool automatically groups targets per arc beam in order to reduce dose to healthy tissue. 💎 Within particle therapy the demonstrations will include LET optimization, proton arc planning and particle dose computation on synthetic CT from CBCT. ❓ If you're interested in physics, upright treatments or other emerging technologies, such as FLASH, I would be very happy to welcome you to our booth to discuss with you in person. 📊 The analytics tools of RayIntelligence are getting boosted with new dashboards with RayCare and RayStation data, giving insights into for example clinic workflows and treatment outcomes.

IRO® brings a new standard to CGT manufacturing 🎉 Last week, Jason C. Foster was joined on stage at ISCT by CTMC Co-Founder and CEO Jason Bock to launch our new CGT manufacturing platform, IRO®, and to share data and insights from CTMC's direct experience using the platform. Our partnership with CTMC provided their the team with pre-commercial access to IRO® to demonstrate its technical feasibility. Compared to the current manufacturing process, IRO® has demonstrated: 🧫 A higher average transduction efficiency of 69% vs 45% 🧫 Consistently higher cell yields 🧫 A rapid process transfer: taking just weeks, rather than the industry's usual 6-9 months This data showcases the ability of the IRO® platform to provide superior biological performance, accelerate therapy development, and scale the clinical and commercial impact of these life-changing therapies. See more data from our partnership with CTMC ➡️ https://lnkd.in/exJpkkzj Schedule a demo to see how IRO® can transform your manufacturing ➡️ https://lnkd.in/eXEXEGZZ #ISCT2024 #AutomatingBetterBiology #CellTherapy #GeneTherapy #Biotechnology CTMC / A joint venture between Resilience + MD Anderson Cancer Center

Connected Insights is an extremely powerful tertiary analysis and reporting platform for comprehensive genomic profiling of cancer. You must see to believe, demos can be set up in a matter of days and a free evaluation trial is included. Reach out! #pathologists #oncologists #labdirectors #tertiaryanalysis

We will be hosting a virtual BEXMAB update event on Tuesday, March 19 at 9am GMT/11.00 EET. During the event we will discuss the latest data from our ongoing BEXMAB study, investigating the safety and efficacy of #bexmarilimab, our wholly owned #immunotherapy candidate, in combination with standard of care in patients with hypomethylating agents (HMAs)-refractory or relapsed #acuteMyeloidLeukemia and #MyelodysplasticSyndromes. Participants of the webcast will include Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki and BEXMAB Principal Investigator, Dr. Maija Hollmén, PhD, Chief Scientific Officer at Faron, Dr. Juho Jalkanen MD, PhD, Chief Operating Officer at Faron and members of Faron’s senior management team. To register visit: https://lnkd.in/d9iHDmKr #Faron #biotech #drugdevelopment #oncology

👀Looking forward to OBN (UK) Ltd’s BioSeed event happening on 11 June, where three of our portfolio companies will be presenting. #BioSeed is OBN's flagship healthcare startup accelerator event, nurturing and showcasing cutting-edge innovations from our member companies. Here are the three o2h Ventures portfolio companies presenting: - Stratosvir Limited is working to tackle the barriers to developing viral immunotherapies for cancer, including allowing intravenous delivery and making it possible to dose multiple times. - Clotprotect Tx is developing first-in-class small molecule CP101 which is a direct plasma inhibitor, which will help in improving the bleeding and survival outcomes compared to SOC to tranexamic acid. This has the potential to transform thrombosis management and save countless lives. - CardiaTec Biosciences is at the forefront of cardiac care innovation with their AI-powered software that enables early detection and management of cardiovascular diseases, improving patient outcomes and quality of life. Excited to see these innovative biotech companies showcased at BioSeed! 🚀

📢 We are very pleased to announce that our portfolio company iOnctura has closed a €80M Series B round, led by new investors Syncona Limited and the European Investment Council. This funding will support the late-stage development of treatments for multiple neglected and hard-to-treat cancers. Since our initial investment in 2019, iOnctura has shown exceptional proof-of-concept data for its drug candidates, roginolisib and cambritaxestat. Roginolisib will be tested in a broader patient population for uveal melanoma, non-small cell lung cancer, and primary myelofibrosis. Cambritaxestat will be further developed for fibrotic cancers like metastatic pancreatic cancer. We're excited to welcome new investors and support iOnctura in advancing these critical treatments. #financing #oncology #drugdevelopment #cancertreatment #cancerresearch

𝐓𝐮𝐛𝐮𝐥𝐢𝐬 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 €𝟏𝟐𝟖𝐌 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁𝟐 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 𝐟𝐨𝐫 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐀𝐃𝐂 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 Tubulis Tubulis GmbH secures €128 million ($138.8 million) Series B2 financing, led by EQT Life Sciences and Nextech Invest Ltd, alongside new US-based funds Frazier Life Sciences and Deep Track Capital, and existing investors. The funding will advance Tubulis’ pipeline of ADCs, with focus on lead candidates TUB-040 and TUB-030 targeting tumor antigens Napi2b and 5T4 respectively. Preclinical data for these candidates will be presented at AACR in April, with Phase 1/2a trials planned for 2024. The capital will also support technology platform expansion and establishment of a US subsidiary. CEO Dominik Schumacher Dominik Schumacher aims to position Tubulis as a global ADC leader, emphasizing the company's unique platform technologies. Christoph Broja and Kanishka Pothula will join Tubulis' Supervisory Board. Kanishka Pothula Kanishka Pothula of Nextech Invest Nextech Invest praises Tubulis' innovative approach to ADC design, foreseeing significant impact on oncology treatment. Christoph Broja of EQT Life Sciences echoes the sentiment, highlighting Tubulis' potential to revolutionize oncology treatments. Tubulis aims to maximize ADC performance through innovation in targeting molecules, payloads, and conjugation technologies, offering revolutionary ADCs with superior properties. #Tubulis #SeriesB2 #ADC #Oncology #Biotech #Investment #Innovation #CancerResearch #AACR #ClinicalTrials

This morning we released news of yet another partner agreement for our #Pharma business. Join us at the upcoming Q3 Earnings call to understand how we expect this to impact our business. #biovicb